Serotonin syndrome & neuroleptic malignant syndrome
SS / NMS · Critical Care / ICU
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Serotonin syndrome and neuroleptic malignant syndrome are drug-induced hyperthermic emergencies with autonomic instability, altered mental state and neuromuscular changes. Distinguishing them (rapid onset with clonus and hyperreflexia versus subacute onset with lead-pipe rigidity and bradyreflexia) guides specific therapy; both need aggressive supportive cooling.
Red flags
- Core temperature above 41 degrees
- Severe rigidity with rising CK
- Haemodynamic instability / arrhythmia
- Seizures or coma
- Rhabdomyolysis with hyperkalaemia and AKI
Assessment
Differential diagnosis
- Serotonin syndrome
- Neuroleptic malignant syndrome
- Malignant hyperthermia
- Anticholinergic toxicity
- Sympathomimetic toxicity
- Meningoencephalitis / sepsis
- Thyroid storm
Investigations
- Medication and overdose history
- Creatine kinase (markedly raised in NMS)
- Core temperature
- Renal function and electrolytes
- ABG and lactate
- Septic/CNS screen to exclude mimics
Management
- Stop the offending drug immediately (serotonergic agents for SS; dopamine antagonists / withdrawn dopamine agonists for NMS)
- Distinguish the syndrome: SS onset within hours with clonus, hyperreflexia, agitation; NMS onset over days with lead-pipe rigidity, bradyreflexia, very high CK
- Provide aggressive supportive care: oxygen, IV fluids, continuous monitoring
- Control hyperthermia with active external cooling; treat temperature above 41 degrees as an emergency
- Control agitation and muscle hyperactivity with benzodiazepines
- For severe hyperthermia or rigidity, consider sedation, paralysis (non-depolarising) and intubation to abolish muscle heat production
- For serotonin syndrome, give cyproheptadine as a serotonin antagonist
- For NMS, consider dantrolene and/or bromocriptine as specific therapy
- Avoid antipyretics (ineffective - heat is from muscle activity) and avoid suxamethonium (hyperkalaemia with rhabdomyolysis)
- Treat rhabdomyolysis with fluids and monitor for AKI and hyperkalaemia
- Manage autonomic instability (labile BP/HR) with short-acting titratable agents
- Monitor until resolution, which is faster for SS (usually 24 h) than NMS (days to weeks)
Drugs & doses
Lorazepam/diazepam IV titrated for agitation and rigidity
Cyproheptadine 12 mg PO/NG then 2 mg 2 hourly (serotonin syndrome)
Dantrolene 1-2.5 mg/kg IV (severe NMS/hyperthermia)
Bromocriptine 2.5 mg PO/NG 8 hourly (NMS)
Non-depolarising paralysis (e.g. rocuronium) for refractory hyperthermia - AVOID suxamethonium
Disposition
ICU with active cooling and toxicology/poisons centre advice; monitor CK and renal function closely.
Complications & pitfalls
- Rhabdomyolysis and AKI
- Hyperthermic multi-organ failure
- DIC
- Arrhythmia and cardiovascular collapse
- Aspiration
- Death
Exam pearls
- Clonus and hyperreflexia point to serotonin syndrome; lead-pipe rigidity with very high CK points to NMS
- Heat comes from muscle activity - benzodiazepines, paralysis and cooling work; antipyretics do not
- Avoid suxamethonium in rhabdomyolysis-prone patients due to hyperkalaemia risk
- Severe hyperthermia above 41 degrees is immediately life-threatening - paralyse and intubate early
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.